Jafron Short Term Investments vs Accounts Payable Analysis

300529 Stock   30.48  0.41  1.36%   
Jafron Biomedical financial indicator trend analysis is infinitely more than just investigating Jafron Biomedical recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Jafron Biomedical is a good investment. Please check the relationship between Jafron Biomedical Short Term Investments and its Accounts Payable accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jafron Biomedical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Short Term Investments vs Accounts Payable

Short Term Investments vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Jafron Biomedical Short Term Investments account and Accounts Payable. At this time, the significance of the direction appears to have strong relationship.
The correlation between Jafron Biomedical's Short Term Investments and Accounts Payable is 0.68. Overlapping area represents the amount of variation of Short Term Investments that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Jafron Biomedical Co, assuming nothing else is changed. The correlation between historical values of Jafron Biomedical's Short Term Investments and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Short Term Investments of Jafron Biomedical Co are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Short Term Investments i.e., Jafron Biomedical's Short Term Investments and Accounts Payable go up and down completely randomly.

Correlation Coefficient

0.68
Relationship DirectionPositive 
Relationship StrengthSignificant

Short Term Investments

Short Term Investments is an item under the current assets section of Jafron Biomedical balance sheet. It contains any investments Jafron Biomedical Co undertook that will expire in less than one year. These accounts contain financial instruments such as stocks or bonds that Jafron Biomedical can easily liquidate in the marketplace.

Accounts Payable

An accounting item on the balance sheet that represents Jafron Biomedical obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Jafron Biomedical are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.
Most indicators from Jafron Biomedical's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Jafron Biomedical current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jafron Biomedical Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
The current year's Tax Provision is expected to grow to about 119.8 M, whereas Selling General Administrative is forecasted to decline to about 363.6 M.
 2021 2022 2023 2024 (projected)
Operating Income1.4B1.0B523.2M528.6M
Total Revenue2.7B2.5B1.9B1.2B

Jafron Biomedical fundamental ratios Correlations

-0.030.960.890.970.890.951.00.980.710.950.610.940.880.950.990.490.920.970.950.950.870.810.910.680.94
-0.03-0.130.24-0.10.2-0.270.00.020.47-0.310.42-0.280.140.05-0.040.660.15-0.180.07-0.050.340.45-0.35-0.28-0.16
0.96-0.130.780.950.760.980.960.960.510.980.40.970.770.90.950.320.820.930.870.890.790.770.920.740.88
0.890.240.780.820.990.750.880.840.860.740.760.710.960.870.880.740.980.820.970.930.890.880.660.30.89
0.97-0.10.950.820.830.940.970.970.650.950.520.960.820.920.980.380.850.960.90.910.840.740.940.70.92
0.890.20.760.990.830.740.870.850.850.750.80.730.980.850.880.720.980.850.970.950.890.850.690.310.92
0.95-0.270.980.750.940.740.940.920.480.990.370.970.760.890.940.250.80.930.850.890.730.680.940.740.89
1.00.00.960.880.970.870.940.980.690.950.580.940.860.940.990.470.910.960.940.930.870.820.90.690.92
0.980.020.960.840.970.850.920.980.680.930.550.950.840.890.960.470.880.950.920.920.910.830.920.680.91
0.710.470.510.860.650.850.480.690.680.470.860.470.780.70.690.850.770.610.780.690.860.710.430.240.67
0.95-0.310.980.740.950.750.990.950.930.470.380.990.760.870.940.230.80.960.860.890.730.660.970.750.91
0.610.420.40.760.520.80.370.580.550.860.380.380.780.650.630.770.70.590.660.620.670.580.350.220.61
0.94-0.280.970.710.960.730.970.940.950.470.990.380.740.860.940.20.780.960.850.880.750.650.990.760.9
0.880.140.770.960.820.980.760.860.840.780.760.780.740.850.880.680.970.860.960.960.850.830.70.310.93
0.950.050.90.870.920.850.890.940.890.70.870.650.860.850.960.470.880.890.890.870.780.770.810.640.86
0.99-0.040.950.880.980.880.940.990.960.690.940.630.940.880.960.470.910.980.930.940.840.780.910.690.93
0.490.660.320.740.380.720.250.470.470.850.230.770.20.680.470.470.650.370.590.530.710.710.130.00.45
0.920.150.820.980.850.980.80.910.880.770.80.70.780.970.880.910.650.860.980.970.870.890.740.340.93
0.97-0.180.930.820.960.850.930.960.950.610.960.590.960.860.890.980.370.860.910.930.790.70.940.710.95
0.950.070.870.970.90.970.850.940.920.780.860.660.850.960.890.930.590.980.910.980.90.850.810.430.96
0.95-0.050.890.930.910.950.890.930.920.690.890.620.880.960.870.940.530.970.930.980.860.820.850.450.99
0.870.340.790.890.840.890.730.870.910.860.730.670.750.850.780.840.710.870.790.90.860.890.70.420.82
0.810.450.770.880.740.850.680.820.830.710.660.580.650.830.770.780.710.890.70.850.820.890.580.30.73
0.91-0.350.920.660.940.690.940.90.920.430.970.350.990.70.810.910.130.740.940.810.850.70.580.760.89
0.68-0.280.740.30.70.310.740.690.680.240.750.220.760.310.640.690.00.340.710.430.450.420.30.760.49
0.94-0.160.880.890.920.920.890.920.910.670.910.610.90.930.860.930.450.930.950.960.990.820.730.890.49
Click cells to compare fundamentals

Jafron Biomedical Account Relationship Matchups

Jafron Biomedical fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets2.5B3.2B4.8B5.4B5.5B5.8B
Other Current Liab131.8M140.8M129.3M5.5M4.9M4.6M
Total Current Liabilities262.6M330.8M386.3M717.2M829.4M870.9M
Total Stockholder Equity2.1B2.8B3.4B3.6B3.1B1.8B
Other Liab51.1M61.5M52.2M125.8M144.7M151.9M
Retained Earnings1.2B1.7B2.3B2.1B2.0B1.0B
Accounts Payable32.8M50.2M60.8M128.5M135.6M142.4M
Cash1.3B1.6B2.3B2.6B2.8B3.0B
Other Assets107.9M102.4M91.6M225.4M259.2M272.2M
Net Receivables169.8M167.4M314.4M221.7M74.9M118.9M
Inventory92.3M120.7M196.5M349.1M385.0M404.2M
Other Current Assets25.9M65.3M75.3M35.6M17.3M26.1M
Total Liab324.1M383.1M1.4B1.8B2.4B2.5B
Intangible Assets48.1M89.9M101.3M100.4M100.4M53.5M
Common Stock417.3M418.7M799.1M805.5M926.3M972.6M
Property Plant Equipment457.6M639.6M905.5M1.3B1.5B1.5B
Net Tangible Assets1.6B2.1B2.7B3.2B3.7B2.0B
Deferred Long Term Liab3.4M14.8M20.4M36.0M41.3M43.4M
Total Current Assets1.6B2.0B3.1B3.3B3.3B2.1B
Non Current Assets Total934.9M1.2B1.8B2.1B2.2B1.3B
Non Currrent Assets Other77.5M58.2M162.8M148.2M107.0M102.3M
Non Current Liabilities Total61.5M52.2M1.0B1.1B1.6B1.6B
Common Stock Shares Outstanding795.5M799.1M805.5M807.7M807.6M880.0M
Net Invested Capital2.1B2.8B4.3B4.8B4.8B3.4B
Net Working Capital1.3B1.7B2.7B2.6B2.5B2.0B
Capital Stock418.7M799.1M805.5M807.7M807.6M743.6M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Jafron Stock

Balance Sheet is a snapshot of the financial position of Jafron Biomedical at a specified time, usually calculated after every quarter, six months, or one year. Jafron Biomedical Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Jafron Biomedical and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Jafron currently owns. An asset can also be divided into two categories, current and non-current.